Deutsche Bank Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces Price Target of $136
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Neurocrine Biosciences with a Buy rating and set a price target of $136 for the company's stock.

December 12, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences receives a Buy rating from Deutsche Bank with a price target of $136, indicating a positive outlook for the stock.
Analyst coverage, especially from a major bank like Deutsche Bank, can significantly influence investor perception and stock price. A Buy rating coupled with a high price target suggests a strong bullish stance on the company's future performance, which can lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100